Clinical Trial Update: PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a PD-1 antibody plus GEMOX as postoperative adjuvant therapy for perihilar cholangiocarcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Perihilar Cholangiocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• OXALIPLATIN (Oxaliplatin)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Perihilar Cholangiocarcinoma | Phase 2 | Status: RECRUITING